Jeroen de Ridder is a principal investigator and associate professor at the Center for Molecular Medicine of the University Medical Center Utrecht, where he leads a research group of around 15 Postdocs, PhD students and other staff. In addition, he is a junior PI at the Oncode institute. As a result of his training at both the Netherlands Cancer Institute and the Delft University of Technology, Jeroen is a bioinformatics scientist with a solid background in computational data science and a strong desire to improve cancer genomics. His research focuses on creating cutting-edge machine-learning-inspired methods to make sense of cancer omics data. To this end, the de Ridder lab has recently proposed a machine learning method to predict treatment benefit to cancer drugs. Moreover, Jeroen's lab is designing novel genomics-based cancer diagnostic methods leveraging whole genome sequencing data and nanopore sequencing data of cell free DNA. 

Jeroen is also the co-founder of Cyclomics, a company that aims at improving cancer diagnosis by detecting tumor circulating DNA in the blood of patients.